| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer … DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ... J Clin Oncol 29 (9), 1125-1132, 2011 | 1410 | 2011 |
| Dosage-sensitive requirement for mouse Dll4 in artery development A Duarte, M Hirashima, R Benedito, A Trindade, P Diniz, E Bekman, ... Genes & development 18 (20), 2474-2478, 2004 | 726 | 2004 |
| Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel M Aapro, PA Abrahamsson, JJ Body, RE Coleman, R Colomer, L Costa, ... Annals of oncology 19 (3), 420-432, 2008 | 581 | 2008 |
| Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status L Costa, LM Demers, A Gouveia-Oliveira, J Schaller, EB Costa, ... Journal of Clinical Oncology 20 (3), 850-856, 2002 | 268 | 2002 |
| Biochemical markers and skeletal metastases LM Demers, L Costa, A Lipton Cancer: interdisciplinary international journal of the American Cancer …, 2000 | 254 | 2000 |
| Impact of skeletal complications on patients’ quality of life, mobility, and functional independence L Costa, X Badia, E Chow, A Lipton, A Wardley Supportive Care in Cancer 16, 879-889, 2008 | 249 | 2008 |
| Effect of bisphosphonates on pain and quality of life in patients with bone metastases L Costa, PP Major Nature Reviews Clinical Oncology 6 (3), 163-174, 2009 | 237 | 2009 |
| The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer–a systematic review D Mendes, C Alves, N Afonso, F Cardoso, JL Passos-Coelho, L Costa, ... Breast Cancer Research 17, 1-14, 2015 | 206 | 2015 |
| Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with … D Henry, S Vadhan-Raj, V Hirsh, R Von Moos, V Hungria, L Costa, ... Supportive Care in Cancer 22, 679-687, 2014 | 193 | 2014 |
| Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel P Hadji, RE Coleman, C Wilson, TJ Powles, P Clézardin, M Aapro, ... Annals of Oncology 27 (3), 379-390, 2016 | 182 | 2016 |
| Biochemical markers of bone turnover in patients with metastatic bone disease LM Demers, L Costa, VM Chinchilli, L Gaydos, E Curley, A Lipton Clinical chemistry 41 (10), 1489-1494, 1995 | 174 | 1995 |
| Markers of bone resorption in patients treated with pamidronate A Lipton, L Demers, E Curley, V Chinchilli, L Gaydos, G Hortobagyi, ... European journal of cancer 34 (13), 2021-2026, 1998 | 167 | 1998 |
| Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function M Mandal, R Vadlamudi, D Nguyen, RA Wang, L Costa, ... Journal of Biological Chemistry 276 (13), 9699-9704, 2001 | 155 | 2001 |
| Portuguese higher education students’ adaptation to online teaching and learning in times of the COVID-19 pandemic: personal and contextual factors MA Flores, A Barros, AMV Simão, D Pereira, P Flores, E Fernandes, ... Higher Education 83 (6), 1389-1408, 2022 | 132 | 2022 |
| Safety and efficacy of bisphosphonates beyond 24 months in cancer patients SM Ali, FJ Esteva, G Hortobagyi, H Harvey, J Seaman, R Knight, L Costa, ... Journal of clinical oncology 19 (14), 3434-3437, 2001 | 127 | 2001 |
| Castration-resistant prostate cancer: mechanisms, targets, and treatment TMS Amaral, D Macedo, I Fernandes, L Costa Prostate cancer 2012, 2012 | 126 | 2012 |
| Targeting bone metastases in prostate cancer: improving clinical outcome JJ Body, S Casimiro, L Costa Nature reviews Urology 12 (6), 340-356, 2015 | 125 | 2015 |
| Consensus on the utility of bone markers in the malignant bone disease setting R Coleman, L Costa, F Saad, R Cook, P Hadji, E Terpos, P Garnero, ... Critical reviews in oncology/hematology 80 (3), 411-432, 2011 | 109 | 2011 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Bone metastasis risk factors in breast cancer C Pulido, I Vendrell, AR Ferreira, S Casimiro, A Mansinho, I Alho, L Costa Ecancermedicalscience 11, 2017 | 106 | 2017 |
